pSivida

pSivida is a leading provider of miniaturised, sustained-release drug delivery products and is continuing the evolution of these systems.
Formerly an ASX-listed company, pSivida's intellectual property portfolio consists of over 150 issued patents in countries including the US, Europe, Japan, China and Australia.
In 2018 pSivida acquired Icon Bioscience in a deal which included $60m in equity and $20 million in debt funding from Essex Woodland Health Partners and involved a name change to EyePoint Pharmaceuticals which will trade soley on the NASDAQ exchange. It is developing products designed to revolutionise treatments, with a primary focus in ophthalmology.